With 2200 global employees, MedImmune comprises almost half of AstraZeneca’s overall R&D portfolio and conducts research into Oncology, Respiratory, Inflammation, Autoimmune, Cardiovascular and Metabolic disease.
The Bradley Lab:
The Bradley lab is currently working in collaboration with MedImmune and receiving tissue from the CBTM for the modelling of human glomerulosclerosis in vitro.